Respiratory Syncytial Virus Infection Management

General Management Principles

The American Academy of Pediatrics recommends adequate hydration and fluid intake assessment for all patients with RSV infection 1
The American Academy of Pediatrics suggests supplemental oxygen should be provided if oxygen saturation falls persistently below 90% in previously healthy infants 1
Analgesics such as acetaminophen or ibuprofen can be used for pain or fever management, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 2
Nasal saline irrigation may provide symptomatic relief in adults with upper respiratory symptoms, according to the American Academy of Otolaryngology-Head and Neck Surgery 2
Hand decontamination before and after patient contact is crucial to prevent nosocomial spread, as emphasized by the American Academy of Pediatrics 1
The American Academy of Pediatrics recommends against the routine use of corticosteroids in the management of bronchiolitis 1
Ribavirin should not be used routinely in children with bronchiolitis, according to the American Academy of Pediatrics 1
Antibacterial medications should only be used when specific indications of bacterial co-infection exist, as recommended by the American Academy of Pediatrics 1

Special Populations

For hematopoietic stem cell transplant patients with RSV lower respiratory tract infectious disease, treatment options include aerosolized ribavirin, as recommended by the Infectious Diseases Society of America 3
Systemic ribavirin can be administered orally or intravenously for patients unable to take oral medication, according to the Infectious Diseases Society of America 3
Combination therapy with intravenous immunoglobulin or anti-RSV-enriched antibody preparations may be considered for hematopoietic stem cell transplant patients, as suggested by the Infectious Diseases Society of America 3

Prevention Strategies

Palivizumab may be administered for prophylaxis in infants with a history of prematurity, as recommended by the American Academy of Pediatrics 1
Palivizumab may be administered for prophylaxis in infants with congenital heart disease, according to the American Academy of Pediatrics 1
Hand decontamination is the most important step in preventing nosocomial spread of RSV, as emphasized by the American Academy of Pediatrics 1
Alcohol-based rubs are preferred for hand decontamination, as recommended by the American Academy of Pediatrics 1
Education of personnel and family members on hand sanitation is essential, according to the American Academy of Pediatrics 1
Infants should not be exposed to passive smoking, as recommended by the American Academy of Pediatrics 1
Breastfeeding is recommended to decrease a child's risk of having lower respiratory tract disease, according to the American Academy of Pediatrics 1

Monitoring and Follow-up

As the child's clinical course improves, continuous measurement of SpO2 is not routinely needed, as recommended by the American Academy of Pediatrics 1
Infants with hemodynamically significant heart or lung disease and premature infants require close monitoring as oxygen is being weaned, according to the American Academy of Pediatrics 1

Clinical Pitfalls to Avoid

Overuse of antibiotics when there is no evidence of bacterial co-infection should be avoided, as recommended by the American Academy of Pediatrics and the American Academy of Otolaryngology-Head and Neck Surgery 1, 2
Continuing bronchodilator therapy without documented clinical improvement should be avoided, as recommended by the American Academy of Pediatrics 1
Inadequate infection control measures leading to nosocomial transmission should be avoided, as emphasized by the American Academy of Pediatrics 1

Respiratory Syncytial Virus (RSV) Infection Management

Clinical Significance and Prevention

RSV is classified into RSV-A and RSV-B subtypes according to variations in the G protein, with a pattern of alternating predominance observed between them 4, 5, 6
The American Thoracic Society recommends that RSV vaccine is indicated for people aged ≥50 years with risk factors and all persons aged ≥60 years 4, 5, 6
If vaccine availability is limited, priority should be given to individuals aged ≥75 years and those aged ≥50 years with risk factors, as recommended by the American College of Physicians 4, 5, 6
Patients with Severe Combined Immunodeficiency (SCID) or suspected SCID should receive prophylaxis with palivizumab during RSV season, as suggested by the American Academy of Allergy, Asthma, and Immunology 7

Special Population Considerations

The American Academy of Pediatrics suggests that early signs of infection should be promptly investigated and antimicrobial regimens initiated early and for prolonged periods in patients with SCID or suspected SCID 7
The Centers for Disease Control and Prevention recommends that RSV infection should be documented by a rapid diagnostic method before or during the first 24 hours of treatment in high-risk populations 7

Treatment of RSV Infection

Primary Treatment Approach

The American Academy of Pediatrics is not cited for this fact, however, palivizumab has no therapeutic benefit for treating established RSV infection—it is only approved for prevention in high-risk infants and should never be used as treatment 8, 9

What NOT to Use

Palivizumab has no therapeutic benefit for treating established RSV infection—it is only approved for prevention in high-risk infants and should never be used as treatment 8, 9

Age-Specific Considerations

Less than 20% of all pediatric RSV hospitalizations occur during the second year of life (75% occur in infants <12 months) 8
RSV hospitalization rates decline significantly after the first year 8
Even children with comorbidities have lower RSV hospitalization rates in the second year compared to healthy term infants in their first year 8

Infection Control

Hand hygiene is the single most important measure to prevent transmission to others 9

RSV Treatment for High-Risk Populations

Antiviral Therapy

Aerosolized ribavirin is the primary treatment option for RSV lower respiratory tract infection in hematopoietic stem cell transplant patients, though based mainly on observational data 10
Oral ribavirin may be an effective and easier-to-administer alternative that can reduce progression to lower respiratory tract infection and mortality in immunocompromised patients 10

Emerging Therapies

Several new antiviral agents and monoclonal antibodies, such as presatovir, ALS-008176, and RSV604, are in various phases of clinical development, which may expand treatment options in the future 10

Management of Respiratory Distress in RSV Infection

Oxygen Therapy and Ventilation

High-flow nasal oxygen (HFNO) may be considered in selected patients with hypoxemic respiratory failure, though patients should be in a monitored setting with experienced personnel capable of intubation, as recommended by the British Medical Journal 11
Non-invasive ventilation (NIV) is generally NOT recommended for RSV infection due to high failure rates and risk of aerosol generation, according to the British Medical Journal 11
Early intubation and invasive mechanical ventilation should be considered if respiratory distress worsens or oxygen requirements cannot be met with standard supplementation, as suggested by the British Medical Journal 11

Medication Management

Ribavirin should NOT be used routinely in children with RSV bronchiolitis, but its use is restricted to severely immunocompromised patients, hematopoietic stem cell transplant patients, and mechanically ventilated infants with documented severe RSV infection, as indicated by the Thorax journal 12

Monitoring and Escalation of Care

Monitor and record mental status, as part of the vital signs, in patients with RSV infection, as recommended by the British Medical Journal 11
Consider transfer to high dependency or intensive care if patient fails to maintain SaO2 >92% in FiO2 >60%, is in shock, or has severe respiratory distress with rising PaCO2 (>6.5 kPa), as suggested by the British Medical Journal 11 and the Thorax journal 13

Management of Pediatric RSV Infection

Ineffective Therapies to Avoid

The American Academy of Pediatrics recommends that palivizumab has no therapeutic benefit for treating established RSV infection, and it is only approved for prevention in high-risk infants 14, 15, 16, 17

Infection Control: Critical for Preventing Nosocomial Spread

The American Academy of Pediatrics emphasizes that hand hygiene is the single most important measure to prevent transmission, and hand decontamination should be performed before and after direct patient contact, after contact with objects near the patient, and after removing gloves 18, 19
The use of alcohol-based rubs is preferred if hands are not visibly soiled, and gloves should be used with frequent changes to avoid spreading organisms on gloves 18, 19
The Centers for Disease Control and Prevention recommends wearing gowns for direct contact with the patient, and education of personnel and family members about prevention is essential 18, 19
Programs implementing strict hand hygiene and droplet precautions have decreased nosocomial RSV transmission by 39-50% 18

RSV Treatment for High-Risk and Immunocompromised Patients

Introduction to RSV Treatment

The Infectious Diseases Society of America recommends ribavirin as the primary antiviral option for hematopoietic stem cell transplant (HSCT) patients and severely immunocompromised individuals with RSV lower respiratory tract infection 20, 21

Ribavirin Administration

The Centers for Disease Control and Prevention indicates that aerosolized ribavirin is FDA-approved for hospitalized infants and young children with severe lower respiratory tract RSV infection, though its use should be limited to truly severe cases 20, 21
Ribavirin is indicated for HSCT patients with RSV lower respiratory tract infectious disease (LRTID) or those at high risk for progression 20, 21
Aerosolized form is the primary option for mechanically ventilated patients with documented severe RSV infection 20
Systemic ribavirin can be administered orally or intravenously (10-30 mg/kg/day in 3 divided doses) for patients unable to take oral medication 20, 21

Dosing Schedule for Systemic Ribavirin

The dosing schedule for systemic ribavirin is as follows:

Monitoring for Ribavirin Adverse Events

Monitor for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function in patients receiving aerosolized ribavirin 20
Monitor for hemolysis, abnormal liver function tests, and declining renal function in patients receiving systemic ribavirin 20, 21
Avoid environmental exposure in pregnant healthcare workers due to teratogenic effects 20

Combination Therapy for HSCT Patients

Consider combining ribavirin with immunoglobulin therapy for allogeneic HSCT patients with RSV LRTID or at high risk for progression 20, 21
Aerosolized or systemic ribavirin may be combined with IVIG or anti-RSV-enriched antibody preparations 20, 21

Timing Considerations for Immunocompromised Patients

Defer conditioning therapy for patients with RSV respiratory tract infection planned for allogeneic HSCT 20, 21
Consider deferring chemotherapy for patients with RSV infection scheduled for hemato-oncological treatment 20, 21

Treatment for RSV in Immunocompromised Adolescents

Special Considerations for High-Risk Patients

The American Academy of Pediatrics recommends that hematopoietic stem cell transplant (HSCT) recipients with RSV infection receive more aggressive management, including consideration of ribavirin therapy 22
The Infectious Diseases Society of America suggests that solid organ transplant recipients with RSV infection may require more intensive care, including supplemental oxygen and close monitoring of respiratory status 23
The American College of Chest Physicians recommends that patients with active chemotherapy for malignancy and RSV infection be closely monitored for respiratory complications and considered for ribavirin therapy 24
The Centers for Disease Control and Prevention advise that patients with HIV infection and significant immunosuppression who develop RSV infection should receive prompt treatment, including consideration of antiviral therapy 25
The European Respiratory Society recommends that patients with chronic immunosuppressive therapy, including high-dose corticosteroids or biologics, who develop RSV infection be closely monitored for respiratory complications and considered for ribavirin therapy 23, 25

Treatment Options for Immunocompromised Patients

The Infectious Diseases Society of America recommends that immunocompromised patients with RSV lower respiratory tract infection receive ribavirin therapy, with options including aerosolized or oral/intravenous administration 22
The American Society of Transplantation suggests that combination therapy with intravenous immunoglobulin (IVIG) or anti-RSV-enriched antibody preparations may be considered for HSCT patients with lower respiratory tract disease 22

Indications for Hospitalization

The American Academy of Pediatrics recommends that patients with underlying immunocompromised status and lower respiratory tract involvement be considered for hospitalization 24

RSV Infection Management in Infants

Infection Control and Prevention

The American Academy of Pediatrics recommends keeping the infant away from crowds and sick contacts to prevent RSV transmission, and encourages breastfeeding to potentially decrease the risk of severe disease 26, 27
The Centers for Disease Control and Prevention recommends newer prevention strategies, including nirsevimab, a long-acting monoclonal antibody for all infants <8 months entering their first RSV season 26, 27

Hospitalization and ICU Criteria

The American Academy of Pediatrics recommends hospitalization if the infant has hypoxemia (SpO2 persistently <90%), signs of severe respiratory distress, inability to maintain adequate oral intake, or underlying high-risk conditions 26, 27
The Society for Pediatric Research recommends escalating to intensive care if the infant has worsening respiratory distress despite supplemental oxygen, oxygen requirement of FiO2 ≥0.50, or development of apnea or persistent grunting 26, 27

RSV Management in High-Risk Infants

Prevention Strategies

The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born before 29 weeks gestation who are younger than 12 months at the start of RSV season 28
Infants born ≤28 weeks gestation may receive prophylaxis during their first RSV season, whenever that occurs during the first 12 months of life, according to the American Academy of Pediatrics 29, 30
The American Academy of Pediatrics suggests that infants born 29-31 weeks gestation may benefit from prophylaxis up to 6 months of age 29, 30
Palivizumab reduces RSV hospitalization by 45-55% in high-risk populations, as stated by the American Academy of Pediatrics 31

Universal Prevention Measures for All Infants

The American Academy of Pediatrics recommends avoiding tobacco smoke exposure completely, as it is a controllable risk factor that increases RSV hospitalization risk 29, 30
Limiting exposure to crowds and group childcare during RSV season (November through March in most regions) is recommended by the American Academy of Pediatrics 29, 30
Keeping infants away from sick contacts and situations where exposure to infected individuals cannot be controlled is advised by the American Academy of Pediatrics 29, 30
The American Academy of Pediatrics suggests encouraging breastfeeding to potentially decrease the risk of lower respiratory tract disease 30
Ensuring influenza vaccination for the infant (starting at 6 months) and all household contacts is recommended by the American Academy of Pediatrics 29, 30

RSV Testing and Management

Clinical Context for Testing Decisions

High-risk populations, such as immunocompromised individuals, transplant recipients, and those with severe underlying cardiopulmonary disease, require risk stratification, and RSV testing may be indicated for these groups, according to the American Academy of Pediatrics 32
Infants receiving palivizumab prophylaxis who develop bronchiolitis should undergo RSV testing to determine if breakthrough RSV infection occurred, which would warrant discontinuation of further prophylaxis, as recommended by the American Academy of Pediatrics 32
Febrile infants ≤60 days old being evaluated for serious bacterial infection should undergo RSV testing, as a positive result reduces (but does not eliminate) the risk of concurrent bacterial infection, with a moderate strength of evidence 33, 34
Routine outpatient bronchiolitis cases where management will be supportive regardless do not require RSV testing, according to the American Academy of Pediatrics 32

RSV Infection Treatment and Prevention

High-Risk Population Management

The American Academy of Pediatrics recommends ribavirin as the primary antiviral option for severely immunocompromised patients, particularly hematopoietic stem cell transplant (HSCT) recipients with RSV lower respiratory tract infection, though evidence is based mainly on observational data 35
Solid organ transplant recipients with severe RSV infection may benefit from ribavirin therapy, as suggested by the Pediatrics journal 36
Patients with profound lymphopenia (<100 cells/mm³) are at high risk for progression to lower respiratory tract disease and may benefit from ribavirin therapy, according to the Pediatrics journal 36

Prevention Strategies

The American Academy of Pediatrics indicates that palivizumab is ONLY for prevention, not treatment, in specific high-risk pediatric populations, including infants born ≤28 weeks gestation and those with bronchopulmonary dysplasia requiring medical treatment within the previous 6 months 37, 38, 39
Palivizumab reduces RSV hospitalization by 45-55% in high-risk populations, as reported by the Pediatrics journal 37, 39

RSV Infection Management in High-Risk Pediatric Populations

High-Risk Populations

Premature infants (≤35 weeks gestation, especially ≤28 weeks) are at high risk for severe RSV infection and require vigilant monitoring 40, 41
Infants with chronic lung disease/bronchopulmonary dysplasia requiring medical treatment within the previous 6 months are at high risk for severe RSV infection and may benefit from palivizumab prophylaxis 42
Children with hemodynamically significant congenital heart disease are at high risk for severe RSV infection and may benefit from palivizumab prophylaxis 40, 43
Immunocompromised patients, particularly those with profound lymphopenia (<100 cells/mm³), are at high risk for severe RSV infection and may benefit from ribavirin treatment 43
Children with neuromuscular disorders impairing secretion clearance are at high risk for severe RSV infection and require vigilant monitoring 41, 43

Prevention Strategies

The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born ≤28 weeks gestation who are <12 months old at the start of RSV season, and for infants with bronchopulmonary dysplasia requiring medical treatment within the previous 6 months 42
Palivizumab dosing is 15 mg/kg intramuscularly monthly throughout RSV season, with a maximum of 5 doses per season 42

Treatment Approach

The American Academy of Pediatrics recommends supportive care as the cornerstone of management for acute RSV infection, with no effective antiviral therapy for routine use 40, 41, 42, 43

RSV Discharge Criteria and Management

Discharge Readiness Criteria

The American Academy of Pediatrics recommends that a child's oxygen saturation should consistently be >90% in room air for at least 12-24 hours before discharge, indicating clinical improvement 44, 45, 46, 47
Clinical improvement, including better activity level, improved appetite, and decreased or absent fever for at least 12-24 hours, is a discharge criterion 44, 45, 46, 47
A child should have a normal or baseline mental status before being discharged 45, 46, 47
The absence of substantially increased work of breathing, sustained tachypnea, or tachycardia is necessary for discharge 44, 45, 46, 47

Warning Signs for Return to Emergency Department

The Centers for Disease Control and Prevention advises that if a child's oxygen saturation falls below 90%, they should return to the emergency department immediately 45, 46, 47
Increased work of breathing, such as visible chest retractions, flaring nostrils, or grunting sounds, is a warning sign for return to the emergency department 44, 45, 46, 47
Rapid breathing that doesn't improve with rest is a concerning symptom requiring immediate medical attention 44, 45, 46, 47
Difficulty breathing or appearing to struggle to breathe warrants an immediate return to the emergency department 45, 46, 47
Lethargy, difficulty waking, or altered mental status are severe symptoms requiring prompt medical evaluation 45, 46, 47

RSV Isolation Duration

Isolation Precautions Framework

The American Academy of Pediatrics recommends that patients with RSV infection should remain in isolation precautions for the duration of their hospitalization or until symptoms resolve, as RSV viral shedding typically continues throughout the acute illness and can persist for 1-3 weeks in infants and young children 48
Standard isolation precautions should include maintaining contact and droplet precautions throughout hospitalization for all RSV-positive patients, regardless of antibiotic use 48
Hand decontamination before and after patient contact is the single most important infection control measure, with alcohol-based rubs preferred when hands are not visibly soiled 48
Healthcare workers must wear gowns for direct patient contact and use gloves with frequent changes to prevent organism spread on contaminated gloves 48

Practical Isolation Implementation

Implementing pediatric droplet precautions for all children <2 years with respiratory symptoms during RSV season until proven RSV-negative can reduce nosocomial transmission, and assigning dedicated staff to RSV-positive patients when feasible (cohorting) can also be effective 48
Educating all personnel and family members on hand sanitation protocols and ensuring alcohol-based hand rub availability at point of care can help reduce transmission 48
Isolation can be discontinued upon hospital discharge if the patient is going home, according to the American Academy of Pediatrics 48

Common Pitfalls to Avoid

The American Academy of Pediatrics advises against discontinuing isolation based on antibiotic treatment duration or clinical improvement alone, as viral shedding persists even as symptoms improve and RSV RNA can be detected in air samples up to 22 feet from the patient's bedside 48

RSV Infection Control and Prevention

Infection Control Measures

The American Academy of Pediatrics recommends that RSV can survive on counter tops for ≥6 hours, on gowns for 20-30 minutes, and on skin for up to 20 minutes, highlighting the importance of proper infection control measures 49
The Centers for Disease Control and Prevention recommends restricting healthcare personnel with upper respiratory infections from caring for high-risk patients, and not allowing persons with respiratory infection symptoms to visit pediatric, immunosuppressed, or cardiac patients 50, 51

Prevention Strategies

The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born ≤28 weeks gestation who are <12 months old at the start of RSV season, and for infants with chronic lung disease of prematurity requiring supplemental oxygen, diuretic therapy, or chronic corticosteroid therapy within 6 months of RSV season onset 52, 53
The American Academy of Pediatrics recommends administering 15 mg/kg intramuscularly monthly throughout RSV season, maximum of 5 doses per season, to provide protection into April 52, 53
Palivizumab reduces RSV hospitalization by 45-55% in high-risk populations, according to the American Academy of Pediatrics 49, 52, 53
Breastfeeding may decrease the risk of lower respiratory tract disease, as suggested by the American Academy of Pediatrics 49

Antiviral and Infection‑Control Strategies for RSV in Highly Immunocompromised Patients

Indications for Ribavirin Therapy

Hematopoietic stem‑cell transplant (HSCT) recipients with RSV lower‑respiratory‑tract infection or at high risk for disease progression should receive ribavirin (population: HSCT patients; intervention: ribavirin; outcome: prevention of progression) 54, 55

Ribavirin Administration and Monitoring

Aerosolized Ribavirin (preferred for mechanically ventilated patients)

Dose options: 2 g administered over 2 h every 8 h, or 6 g continuously over 18 h per day for 7–10 days (intervention: aerosolized ribavirin dosing schedule) 54, 55, 56
Adverse‑event monitoring: watch for claustrophobia, bronchospasm, nausea, conjunctivitis, and declining pulmonary function (outcome: early detection of toxicity) 54, 55, 56
Safety precautions: implement environmental controls and protect pregnant healthcare workers from teratogenic exposure (intervention: exposure‑avoidance measures) 54, 55, 56

Systemic Ribavirin (oral or intravenous)

Day 1 regimen: 600 mg loading dose followed by 200 mg every 8 h (intervention: initial systemic dosing) 57
Day 2 regimen: 400 mg every 8 h (intervention: continuation dosing) 57
From Day 3 onward: increase to a maximum of 10 mg/kg every 8 h (intervention: dose escalation based on weight) 54, 55, 56, 57
Renal‑impairment adjustment: for creatinine clearance 30–50 mL/min, limit to 200 mg every 8 h (population: patients with moderate renal dysfunction) 57
Adverse‑event monitoring: assess for hemolysis, abnormal liver‑function tests, and worsening renal function (outcome: safety surveillance) 54, 55, 56

Combination Therapy for HSCT Patients

Add‑on therapy: aerosolized or systemic ribavirin may be combined with intravenous immunoglobulin (IVIG) or anti‑RSV‑enriched antibody preparations in allogeneic HSCT recipients with RSV lower‑respiratory‑tract disease or high risk of progression (population: allogeneic HSCT; intervention: ribavirin + IVIG/antibody; outcome: enhanced viral control) 54, 55, 56

Palivizumab Prophylaxis in HSCT

Prophylactic use: monthly intramuscular palivizumab (15 mg/kg) throughout RSV season is recommended for very young (<2 years) allogeneic HSCT patients with lower‑respiratory‑tract disease or high risk of progression; recommendation is weak with limited supporting evidence (population: young HSCT recipients; intervention: palivizumab prophylaxis; outcome: reduced RSV incidence) 55, 56, 58

Timing of Conditioning and Chemotherapy

Allogeneic HSCT conditioning: defer conditioning therapy in patients who have an active RSV respiratory‑tract infection (population: patients scheduled for HSCT; intervention: postponement of conditioning; outcome: avoidance of severe RSV complications) 54, 55, 56
Hemato‑oncologic chemotherapy: consider deferring chemotherapy in patients with RSV infection who are slated for treatment (population: patients awaiting chemotherapy; intervention: treatment delay; outcome: reduced risk of RSV‑related morbidity) 54, 55

Infection‑Control Measures

Personal protective equipment: healthcare workers should wear gowns and change gloves frequently when providing direct patient care (intervention: gown and glove use) 59
Visitor restrictions: individuals with respiratory symptoms should be barred from visiting pediatric, immunosuppressed, or cardiac patients (population: vulnerable patients; intervention: symptom‑based visitor exclusion) 59

Prevention and Risk Reduction for RSV in Infants

Environmental Exposure

Avoid exposure to tobacco smoke, as it increases the risk of severe RSV disease in infants. 60

Feeding Practices

Continue breastfeeding when possible, because breast milk may lower the likelihood of severe RSV infection in young infants. 60

Prophylactic Monoclonal Antibody Eligibility

Palivizumab prophylaxis is recommended only for infants who meet high‑risk criteria (e.g., born at ≤28 weeks gestation, have chronic lung disease requiring therapy, or possess hemodynamically significant congenital heart disease); otherwise, it is not indicated for routine RSV prevention. 60

Evidence‑Based RSV Prophylaxis and Risk Stratification

Palivizumab Prophylaxis Recommendations

The American Academy of Pediatrics recommends monthly intramuscular palivizumab (15 mg/kg) throughout the RSV season for infants and children who meet defined high‑risk criteria [61][62]63.
Infants born at ≤28 weeks gestational age and younger than 12 months at the start of RSV season are eligible for palivizumab prophylaxis [61][63].
Infants with chronic lung disease/bronchopulmonary dysplasia who require medical therapy (supplemental oxygen, diuretics, or chronic corticosteroids) within 6 months of RSV season onset qualify for prophylaxis 63.
Children ≤24 months old with hemodynamically significant congenital heart disease should receive palivizumab [61][63].

Efficacy and Limitations of Palivizumab

The IMpact‑RSV randomized trial demonstrated a 55 % relative reduction in RSV‑related hospitalization (10.6 % placebo vs 4.8 % palivizumab) among high‑risk infants 63 (Level I evidence – randomized controlled trial).
Despite this benefit, palivizumab has minimal effect on the overall RSV disease burden, because the majority of RSV hospitalizations occur in healthy term infants who are not eligible for prophylaxis [62][63].
No randomized clinical trial has shown a statistically significant reduction in RSV‑related mortality with palivizumab 64.
Prophylaxis is not recommended during the second year of life for most children; RSV hospitalization rates in the second year (≈18 per 1,000 for children with congenital heart disease) are less than half the rate in low‑risk infants during the first five months of life (≈44 per 1,000) 61.

High‑Risk Populations for Severe RSV

Profound lymphopenia (<100 cells/mm³) in immunocompromised patients is a strong predictor of progression to lower‑respiratory‑tract RSV disease 61.
Hemodynamically significant congenital heart disease markedly increases the risk of severe RSV infection 61.
Immunocompromised patients with profound lymphopenia (as above) are at heightened risk for severe disease 61.
Neuromuscular disorders that impair secretion clearance are associated with increased severity of RSV infection 61.

Modifiable Protective Factors

Breastfeeding may lower the risk of lower‑respiratory‑tract RSV disease in infants [62][63].

Palivizumab Prophylaxis and Infection‑Control Guidelines for RSV in Pediatric Patients

Indications for Palivizumab Prophylaxis (First Year of Life)

The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born before 29 weeks 0 days gestation. 65
The AAP also recommends prophylaxis for infants born <32 weeks 0 days gestation who required ≥28 days of supplemental oxygen after birth and who continue to need oxygen or chronic systemic therapy. 65
Children ≤24 months old with hemodynamically significant congenital heart disease are eligible for prophylaxis. 65
Infants with pulmonary abnormalities or neuromuscular disease that impair secretion clearance may be considered for prophylaxis. 65

Situations in Which Palivizumab Is Not Recommended

The AAP advises against prophylaxis for otherwise healthy infants born at or after 29 weeks 0 days gestation. 65
Routine use in cystic fibrosis patients is not recommended unless other high‑risk criteria are met. 66
Palivizumab should not be used for primary asthma prevention, to reduce subsequent wheezing episodes, or to treat active RSV infection. 65
It is not indicated for controlling RSV outbreaks in healthcare settings. 66

Dosing and Administration of Palivizumab

15 mg/kg intramuscularly once monthly for a maximum of five doses per RSV season. 65
The first dose should be given in November (or October in some regions) and continued monthly to provide protection through April (or February for an October start). 65
For infants in a neonatal unit who qualify, the first dose may be administered 48–72 hours before discharge or promptly after discharge. 65

Second‑Year Prophylaxis Recommendations

The AAP recommends a second season of palivizumab only for preterm infants born <32 weeks 0 days gestation who required ≥28 days of supplemental oxygen after birth and who continue to need oxygen or chronic systemic therapy. 66
Additional candidates include infants with severe lung disease (hospitalization for pulmonary exacerbation in the first year or persistent imaging abnormalities) or weight‑for‑length <10th percentile. 66

Discontinuation of Prophylaxis After Hospitalization

Prophylaxis should be discontinued after an RSV hospitalization because the likelihood of a second RSV hospitalization in the same season is <0.5%. 66

Infection‑Control Measures in Healthcare Settings

Hand decontamination before and after patient contact is identified as the single most important step to prevent nosocomial RSV spread. 65
Alcohol‑based hand rubs are preferred when hands are not visibly soiled. 65
Gown use for direct patient contact and frequent glove changes are recommended. 65
Contact and droplet precautions should be applied to all RSV‑positive patients. 65
Cohorting patients and staff during outbreaks helps limit transmission. 65
Education of personnel and families on hand‑sanitation protocols is essential. 65

All bullet points are derived from cited evidence in the American Academy of Pediatrics guidelines (Pediatrics, 2014) and are presented in English with patient identifiers generalized.

Palivizumab Recommendations for RSV Prevention and Therapeutic Use

Prophylaxis Eligibility

The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born before 29 weeks gestation who are younger than 12 months at the start of the RSV season. 67
The American Academy of Pediatrics recommends palivizumab prophylaxis for infants with chronic lung disease (bronchopulmonary dysplasia) requiring medical therapy (e.g., supplemental oxygen, diuretics, or chronic corticosteroids) within 6 months of RSV season onset. 67
The American Academy of Pediatrics recommends palivizumab prophylaxis for children ≤24 months with hemodynamically significant congenital heart disease. 67
The American Academy of Pediatrics suggests considering palivizumab prophylaxis for profoundly immunocompromised children younger than 24 months during the RSV season. 67

Dosing Recommendations

Palivizumab is administered at 15 mg/kg intramuscularly each month throughout the RSV season, with a maximum of five doses per season. 67
After cardiac bypass surgery, an additional post‑operative dose of palivizumab is advised because serum concentrations decrease by approximately 58 %. 67

Discontinuation Criteria

Palivizumab prophylaxis should be discontinued if a breakthrough RSV hospitalization occurs, as the likelihood of a second RSV hospitalization in the same season is < 0.5 %. 67

Efficacy

In high‑risk populations, palivizumab reduces RSV‑related hospitalizations by 45–55 %, although it has no measurable effect on mortality and only a minimal impact on subsequent wheezing. 67

Therapeutic Use (What Not to Do)

The American Academy of Pediatrics states that palivizumab has no therapeutic benefit for treating established RSV infection and should be used only for prevention in high‑risk infants. 67